Alzai Health Corp. Announces TSX Venture Exchange Listing

• Alzai Health Corp. has received final approval from the TSX Venture Exchange to list its common shares, pending the closing of its previously announced initial public offering.
• The IPO consists of 8,000,000 to 10,000,000 units priced at $0.40 per unit, targeting gross proceeds of $3.2 million to $4.0 million.
• Each unit comprises one common share and one-half of one common share purchase warrant.
• Investor warrants carry a $0.60 exercise price, expire 24 months post-closing, and include an acceleration clause if the stock trades at or above $0.90 for 10 consecutive days.
• Haywood Securities Inc. acts as the exclusive best-efforts agent, earning a 7% cash commission (reduced to 2% for president’s list investors) plus a $45,000 corporate finance fee.
• Common shares will begin trading under the ticker “ALZI” on June 9, 2026, following the lifting of an immediate trading halt.
• The company develops an AI-driven, non-invasive Alzheimer’s disease risk screening solution that leverages pre-existing clinical data to enable earlier diagnosis and intervention.

• The June 5 announcement is a procedural milestone that confirms the TSXV listing approval and sets the trading commencement date. It contains no new pricing, structural, or strategic changes compared to the April 22 prospectus filing.
• The offering terms remain identical: $0.40 per unit, 8-10M units, $3.2-4.0M gross proceeds. This indicates the company successfully navigated regulatory review without diluting the offering size or price.
• From a risk perspective, the capital raise is modest for a healthcare/AI diagnostic venture. Proceeds are allocated to R&D, sales/marketing, and working capital, which is typical for pre-revenue biotech-adjacent companies but highlights a high burn rate expectation.
• The warrant structure introduces near-term dilution risk. The acceleration clause at $0.90 (a 125% premium to the IPO price) is aggressive and may pressure early trading if management seeks to retire warrants quickly.
• Overall, the news is positive in that it transitions the company to a public market, but it is entirely routine. It does not de-risk the underlying technology, validate clinical efficacy, or alter the fundamental investment thesis.

• Alzai Health Corp. is a pre-revenue healthcare technology company focused on early Alzheimer’s disease detection.
• Flagship project: An AI-driven, non-invasive risk screening solution that analyzes pre-existing clinical data to identify at-risk patients earlier than traditional methods.
• Development stage: Pre-IPO, likely in the validation or early clinical trial phase. No commercial revenue or regulatory approvals are disclosed.
• Target market: Healthcare providers, diagnostic labs, and potentially insurance or pharma partners seeking early intervention tools for neurodegenerative diseases.